Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 14/12/2017
SIETES contiene 92152 citas

 
 
 1 a 8 de 8 
Presentar resultados
Seleccionar todas
1. Cita con resumen
Engel P, Almas MF, De Bruin ML, Starzyk K, Blackburn S, Dreyer AN. Lessons learned on the design and the conduct of Post-Authorization Safety Studies: review of 3 years of PRAC oversight. Br J Clin Pharmacol 2017;83:884-93. [Ref.ID 101970]
3.Enlace a cita original Cita con resumen
Sabaté M, Pacheco JF, Ballarín E, Ferrer P, Petri H, Hasford J, Schoonen MW, Rottenkolber M, Fortuny J, Laporte JR, Ibáñez L, on behalf of the PROTECT work package 2. A compilation of research working groups on drug utilisation across Europe. BMC Research Notes 2014;7:143. [Ref.ID 97264]
4. Cita con resumen
The PLoS Medicine Editors. Why drug safety should not take a back seat to efficacy. PLOS Medicine 2011;8:e1001097. [Ref.ID 91252]
5. Cita con resumen
PLoS Medicine editors. Why drug safety should not take a back seat to efficacy. PLOS Medicine 2011;8:1-3. [Ref.ID 90256]
6. Cita con resumen
Schneeweiss S, Avorn J. Postmarketing studies of drug safety. BMJ 2011;342:344-5. [Ref.ID 90208]
7. Cita con resumen
Garattini S, Bertele V. Rosiglitazone and the need for a new drug safety agency. BMJ 2010;341:781-2. [Ref.ID 89479]
8.Enlace a cita original Cita con resumen
Schofield I. Public to gain access to EU side-effect reports. Scrip 2009;3427:6. [Ref.ID 85012]
Seleccionar todas
 
 1 a 8 de 8